Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Synaptic plasticity and mood disorders.

R S Duman1

  • 1Division of Molecular Psychiatry, Abraham Ribicoff Research Facilities, Connecticut Mental Health Center, Yale University School of Medicine, New Haven, CT, USA. ronald.duman@yale.edu

Molecular Psychiatry
|May 3, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prefrontal cortex astroglia modulate anhedonia-like behavior.

Molecular psychiatry·2023
Same author

Prefrontal Cortex Astroglia Modulate Anhedonia-like Behavior.

Research square·2023
Same author

BDNF release and signaling are required for the antidepressant actions of GLYX-13.

Molecular psychiatry·2017
Same author

Transiently increased glutamate cycling in rat PFC is associated with rapid onset of antidepressant-like effects.

Molecular psychiatry·2016
Same author

Remodeling of axo-spinous synapses in the pathophysiology and treatment of depression.

Neuroscience·2012
Same author

The roles of neurotrophic factor and Wnt signaling in depression.

Clinical pharmacology and therapeutics·2011

Molecular mechanisms of neuronal plasticity, including cAMP response element binding protein and brain-derived neurotrophic factor, are key in treating mood disorders. Atypical antipsychotics may also modulate these pathways for therapeutic benefit.

Area of Science:

  • Neuroscience
  • Molecular Psychiatry
  • Pharmacology

Background:

  • Neuronal plasticity is crucial for learning and memory.
  • Molecular regulators of plasticity are implicated in mood disorder treatments.
  • Atypical antipsychotics show efficacy in bipolar disorder and unipolar depression.

Purpose of the Study:

  • To explore the role of neuronal plasticity in mood disorder treatment.
  • To investigate if atypical antipsychotics influence plasticity mechanisms relevant to mood disorders.

Main Methods:

  • Review of recent studies on molecular elements regulating neuronal plasticity.
  • Analysis of the involvement of transcription factors (e.g., cAMP response element binding protein) and neurotrophic factors (e.g., brain-derived neurotrophic factor).

Related Experiment Videos

  • Discussion of the potential impact of atypical antipsychotics (clozapine, olanzapine) on these molecular determinants.

    • Main Results:

    • Up-regulation of cAMP response element binding protein and brain-derived neurotrophic factor is observed in response to mood disorder treatments.
    • These molecular changes suggest a role for neuronal plasticity in therapeutic interventions for mood disorders.
    • Atypical antipsychotics may target the same molecular pathways.

    Conclusions:

    • Regulation of neuronal plasticity in specific circuits is integral to mood disorder therapy.
    • Atypical antipsychotics might exert their therapeutic effects by influencing the molecular determinants of synaptic plasticity.
    • Further research is warranted to elucidate the precise mechanisms by which atypical antipsychotics impact neuronal plasticity in mood disorders.